Cancer immunotherapy
Cancer Immunotherapy[edit]
Introduction[edit]
Cancer Immunotherapy, also known as immuno-oncology, is a form of cancer treatment that involves artificially stimulating the immune system to combat cancer. This approach builds upon the natural ability of the immune system to fight disease and is rooted in the fundamental research of cancer immunology. It represents a growing subspecialty within the field of oncology.
Historical Background[edit]
The concept of cancer immunotherapy dates back over a century, but significant advancements were made in the late 20th and early 21st centuries. In 2018, James P. Allison from the United States and Tasuku Honjo from Japan were awarded the Nobel Prize in Physiology or Medicine for their pioneering work in the inhibition of negative immune regulation in cancer therapy.
Mechanisms of Action[edit]
Cancer immunotherapy works by various mechanisms, each aiming to enhance the immune system's ability to detect and attack cancer cells. These mechanisms include the use of monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines, and adoptive cell transfer.
Types of Immunotherapies[edit]
Checkpoint Inhibitors[edit]
Checkpoint inhibitors, like those discovered by Allison and Honjo, are drugs that help the immune system recognize and attack cancer cells.
Monoclonal Antibodies[edit]

These are laboratory-made molecules that can bind to specific targets on cancer cells, marking them for destruction by the immune system.
Cancer Vaccines[edit]
Cancer vaccines are designed to elicit an immune response against certain cancer-specific antigens.
Adoptive Cell Transfer[edit]
This therapy involves modifying a patient's own immune cells to fight cancer more effectively.
Clinical Applications[edit]
Immunotherapy has been successful in treating various types of cancers, including melanoma, lung cancer, kidney cancer, and more. Its application is rapidly expanding with ongoing research and clinical trials.
Challenges and Future Directions[edit]
While immunotherapy has shown promise, it also presents challenges like managing immune-related side effects and understanding why it works effectively for some patients but not others. Future research is focused on identifying new targets, improving response rates, and combining immunotherapy with other treatments.
See Also[edit]
References[edit]
<references/> 1. Nobel Prize in Physiology or Medicine 2018 2. National Cancer Institute - Immunotherapy
External Links[edit]
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian